

## Press release

### **Esaote continues to invest in Preventive Healthcare and presents MyLabTMOne Vascular, the first tablet-size ultrasound system dedicated to vascular care**

Today's healthcare systems require reliable diagnostic capabilities and high level of productivity. At the same time, scientific societies have also realized the big potential of preventive medicine. An early management of cardiovascular diseases brings better patient care and reduces social and economical impacts.

For many years Esaote has been investing in this challenging field and MyLabTMOne Vascular is a clear prove that prevention, diagnosis and productivity may coexist in a versatile and compact ultrasound system that also includes advanced technologies for vascular care.

"In addition to traditional CVD risk parameters, such as cholesterol and blood pressure values, also intima media thickness (IMT) and arterial stiffness (AS) values are very useful to understand arteriosclerosis, its severity and progression." said Prof. Pierre Boutouyrie, Department of Pharmacology, **European Hospital Georges Pompidou**. "An accurate management of cardiovascular disease at an early stage, provides advantages in the definition of an efficient diagnostic and treatment plan".



MyLabTMOne Vascular is the first tablet-size ultrasound dedicated to vascular care that delivers: simple and user-friendly interface based on full touch-screen display, interchangeable probes, long-life battery, internal archive and wireless connectivity for data sharing. From the clinical point of view, the system is even more outstanding: in addition to high quality standard B-mode, Color and Doppler it includes exclusive technology to measure intima media thickness (IMT) and arterial stiffness (AS) on the basis of radiofrequency signal analysis.

"In the design of MyLabTMOne Vascular we wanted to provide something special to all physicians who are involved in and committed to preventive medicine." said Joop Geijsen, Project Manager at Esaote "That's why we did our best to integrate such an innovative technological package in an easy to use and compact system"

During the EuroPrevent Congress on 18-20 April in Rome, Esaote will showcase the MyLabTMOne Vascular as well as the MyLabTMTwice, MyLabTM Seven and MyLabTMApha, providing a wide range of solutions to satisfy any cardiovascular clinical setting. Visit the booth (A200) to get to know the innovative ultrasound systems for preventative medicine.

With about 327 millions euro consolidated sales (70% of which coming from the international markets) the Esaote Group is leader in the sector of biomedical equipment (in particular, ultrasound, dedicated magnetic resonance and software to manage the diagnostic process). Today Esaote gives work to over 1360 employees, 20% of which employed in the R&D activities. Esaote is present with its industrial and research units in Italy (Genoa, Florence, Naples) in the Netherlands (Maastricht), and in China (Shenzhen). Esaote is internationally recognized to be one of the "Top Ten" world's leading diagnostic imaging companies. Esaote S.p.A. is owned by Ares (39,8%), IMI Investimenti of Intesa Sanpaolo Group (19,2%), Equinox (13,2%), MP Venture (13,2%), Carige (8,2%) and by 100 managers and directors of the Group (6,4%).

Information concerning Esaote and its products are available on the Internet site at the address <http://www.esaote.com>

Genoa, April 17<sup>th</sup> 2013